SK Biopharmaceuticals Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:SK Biopharmaceuticals Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12377
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a researcher and developer of drugs. The company develops and markets drugs for the treatment of central nervous system. It provides plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL-A4R, SKL-PSY and FZ-016; SKL-ADHD and carisbamate drugs, among others. SK Biopharmaceuticals offers research and development; biological studies, preclinical studies, lead compound development and phase development services. The company provides development of next-generation drugs that maintains efficacy and minimizes side-effects and toxicity by harnessing life science technologies in new drug and development programs. It has developed drug candidates in the area of CNS such as epilepsy and GI with chronic constipation and constipation dominant irritable bowel syndrome. SK Biopharmaceuticals is headquartered in Seongnam, South Korea.

SK Biopharmaceuticals Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
SK Biopharma Forms Joint Venture with Glycyx Therapeutics 11
SK Biopharma And AriBio Enter Into Co-Development Agreement For SKL-G 12
SK Biopharma Enters Into Co-Development Agreement With SK Chemicals For YKP-10811 13
SK Biopharma Enters Into Collaboration Agreement With PKU International HealthCare And Shanghai Medicilon 14
Acquisition 15
SK Holdings Acquires SK Biotech from SK Biopharma 15
SK Biopharmaceuticals Co Ltd – Key Competitors 16
SK Biopharmaceuticals Co Ltd – Key Employees 17
SK Biopharmaceuticals Co Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Product News 19
05/24/2017: Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS 19
Clinical Trials 20
Jun 06, 2017: Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy 20
Jun 06, 2017: Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea 22
May 24, 2017: Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting 24
Apr 26, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness 26
Mar 20, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea 28
Feb 08, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson’s Disease 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SK Biopharmaceuticals Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
SK Biopharma Forms Joint Venture with Glycyx Therapeutics 11
SK Biopharma And AriBio Enter Into Co-Development Agreement For SKL-G 12
SK Biopharma Enters Into Co-Development Agreement With SK Chemicals For YKP-10811 13
SK Biopharma Enters Into Collaboration Agreement With PKU International HealthCare And Shanghai Medicilon 14
SK Holdings Acquires SK Biotech from SK Biopharma 15
SK Biopharmaceuticals Co Ltd, Key Competitors 16
SK Biopharmaceuticals Co Ltd, Key Employees 17
SK Biopharmaceuticals Co Ltd, Subsidiaries 18

List of Figures
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[SK Biopharmaceuticals Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ngai Hing Hong Co Ltd (1047):企業の財務・戦略的SWOT分析
    Ngai Hing Hong Co Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cypark Resources Berhad (CYPARK):電力:M&Aディール及び事業提携情報
    Summary Cypark Resources Berhad (CRB) is a clean technology company that offers environmental engineering services. The company offers engineering and technology services on transforming dump sites to an economic and environmental boon. Its services include environmental remediation, integrated wast …
  • Academic Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Academic Medical Center (AMC), a subsidiary of University of Amsterdam is a medical center that offers research and educational services. The center offers services such as medical research, treatment of patients, and medical education services, among others. It provides its medical treatmen …
  • Southern Co (SO):企業の財務・戦略的SWOT分析
    Southern Co (SO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Sinotrans Ltd:企業の戦略・SWOT・財務情報
    Sinotrans Ltd - Strategy, SWOT and Corporate Finance Report Summary Sinotrans Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Spanish National Cancer Research Center-製薬・医療分野:企業M&A・提携分析
    Summary Spanish National Cancer Research Center (CNIO) is a medical research center that offers cancer research programs. The center is an integral cancer research institute which integrates basic and translational cancer research. It conducts various scientific programs which include molecular onco …
  • Enea SA (ENA):企業の財務・戦略的SWOT分析
    Enea SA (ENA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Glomac Berhad:企業の戦略・SWOT・財務情報
    Glomac Berhad - Strategy, SWOT and Corporate Finance Report Summary Glomac Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Superior Energy Services Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Superior Energy Services Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Superior Energy Services Inc (Superior Energy) is a provider of equipment and production services to the energy industry. It offers drilling, completion and production-related services to in …
  • National Industrialization Co (2060):企業の財務・戦略的SWOT分析
    National Industrialization Co (2060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Haisco Pharmaceutical Group Co Ltd (002653):医療機器:M&Aディール及び事業提携情報
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations. The company offers parenteral nutrition drugs, first-aid drugs, antibiotics, anesthetic agents, nervous system drugs, digestive sy …
  • Industrial Bank Co., Ltd.:企業の戦略・SWOT・財務分析
    Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AutoNation Inc (AN):企業の財務・戦略的SWOT分析
    AutoNation Inc (AN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Gunvor Group Ltd:企業の戦略的SWOT分析
    Gunvor Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • CMP Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CMP Pharma Inc (CMP Pharma), formerly Carolina Medical Products Company Inc is a specialty pharmaceutical company that develops and manufactures generic prescription, non-prescription and skin care products. The company’s prescription products include SPS suspension, isoniazid oral solution …
  • Greer Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Greer Laboratories Inc (Greer), a subsidiary of Stallergenes Greer plc, is a pharmaceutical company that provides allergy immunotherapy products and services to the healthcare industry. The company provides products in the area of human allergy, veterinary allergy and source materials. It of …
  • Secom Co., Ltd.:企業の戦略・SWOT・財務情報
    Secom Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Secom Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Torraspapel, S.A.:企業の戦略的SWOT分析
    Torraspapel, S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ChanTest Corp-製薬・医療分野:企業M&A・提携分析
    Summary ChanTest Corp (ChanTest), a subsidiary of Charles River Laboratories International Inc is a contract research organization that discovers and develops drugs in ion channel and GPCR biology fields. The organization's ion channel products include cell lines and antibodies. Its other products c …
  • NAPEC Inc:電力:M&Aディール及び事業提携情報
    Summary NAPEC Inc (NAPEC), is a subsidiary of Oaktree Capital Management, L.P., is an energy services company that provides construction and maintenance services. It builds and maintains electrical transmission and distribution systems, solar panel farms, and natural gas networks. The company instal …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆